PLX:NYE-Protalix Biotherapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.01

Change

-0.06 (-5.61)%

Market Cap

USD 0.07B

Volume

0.20M

Analyst Target

USD 9.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

N/A

USD 585.29B
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 3.60B
RCUS Arcus Biosciences Inc

N/A

USD 1.48B
NUVB Nuvation Bio Inc

N/A

USD 0.70B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.35B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.34B
ADCT ADC Therapeutics SA

N/A

USD 0.30B
CYBN Cybin Inc

N/A

USD 0.16B
ANVS Annovis Bio Inc

N/A

USD 0.10B
MAIA MAIA Biotechnology Inc.

N/A

USD 0.08B

ETFs Containing PLX

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -43.26% 41% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.26% 41% F 4% F
Trailing 12 Months  
Capital Gain -46.56% 29% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.56% 29% F 4% F
Trailing 5 Years  
Capital Gain -54.09% 55% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.09% 55% F 7% C-
Average Annual (5 Year Horizon)  
Capital Gain 9.63% N/A N/A 68% D+
Dividend Return 9.63% N/A N/A 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 109.03% N/A N/A 7% C-
Risk Adjusted Return 8.83% N/A N/A 32% F
Market Capitalization 0.07B 62% D 23% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector